Accesswire
29 Sept 2026, 08:30 UTC · 54m ago
Verdict
Headline takes no side. We score JAGX +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
Jaguar Health targets a New Drug Application (NDA) filing for crofelemer in treating Microvillus Inclusion Disease (MVID) by mid-2027.
Newpress release dated September 29, 2026
So whatThis creates a concrete binary catalyst for the stock within the next 21 months, potentially shifting the valuation from R&D to pre-commercial.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Results from the Phase 2 clinical trial of crofelemer in adult Type 1 short bowel syndrome (SBS) patients are expected early in the second half of 2027.
Newpress release dated September 29, 2026
So whatCombined with the MVID filing, this creates a high-volatility window in H2 2027 that will determine the drug's total addressable market.
More positive than 79% of claims this week
Preliminary results from an open-label study of crofelemer in adult SBS-IF patients will be presented at the ACG 2026 meeting between October 9-14, 2026.
Newpress release dated September 29, 2026
So whatThis provides a short-term data catalyst in less than 11 days that could influence investor sentiment ahead of the 2027 milestones.
More positive than 66% of claims this week
Pediatric investigations of liquid oral crofelemer have shown substantial reductions in weekly parenteral support (PS) needs for patients dosed for over one year.
Priced indata presented in June 2026
So whatWhile positive, these pediatric results were disclosed 3 months ago and are now primarily serving as proof-of-concept for the adult trials.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company's clinical results were accepted for presentation at a major scientific meeting and it is progressing toward an NDA filing.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
1h ago
—
JAGX hasn't traded since this ran. Last close $6.02 (Sep 28); the reaction starts at the next open.
JAGX chart →
